Irritable Bowel Syndrome
Environmental risk factors that predispose people to inflammatory bowel disease may have a stronger effect in children than adults.
Interferon- concentrations and THELPER cells are significantly reduced during symptom flares.
The FDA has received 120 reports of serious cases of pancreatitis or death after the approval of Viberzi in May 2015.
Patients diagnosed with upper functional gastroenterology disorders often have irritable bowel syndromeSeptember 30, 2016
The risk factors for IBS-FD overlap deserve more concern, according to the authors.
Two new therapies to treat irritable bowel syndrome, eluxadoline and rifaximin, have been approved by the FDA.
New guidelines for irritable bowel syndrome treatment have been released by the American Gastroenterological Association.
Trends observed toward improvement in health-related quality of life and self-efficacy in children.
Activated charcoal is a relatively benign product with a low risk profile.
Classifying abdominal pain-related disorders can help determine which patients with IBS should be screened for celiac disease.
Linzess sanctioned for constipation that does not respond to conventional treatment.
Which serologic measure of inflammation is the most cost-effective and reliable when monitoring inflammatory disease?
Esophagogastroduodenoscopy, colonoscopy, complement fixation, celiac, sonogram, gynecologic workup and routine labs have all been negative in a teen with a three-year history of recurrent chronic abdominal pain and diarrhea. What steps should be taken next?
A clinician notices that many of her patients with low vitamin B12 levels also have irritable bowel syndrome.
Strong evidence indicates that mesalamine, sulfasalazine, and other 5-aminosalicylic drugs effectively induce remission in mild-to-moderately active ulcerative colitis (UC) and prevent relapse in quiescent UC.
Is sertraline effective as an off-label treatment for irritable bowel syndrome?
A preparation of the gut-selective, broad-spectrum antibiotic rifaximin has been denied approval for the proposed indication of treatment of non-constipation irritable bowel syndrome and IBS-related bloating.
The authors place particular emphasis on the IBS's status as a true disease as opposed to a figment of the patient's imagination.